The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) September 26, 2022
✳️ 10 tweet #NephJC catch-up ✳️
Did you ever think of using acetazolamide for acute congestive heart failure?
Read on to see whether we should or we should not! pic.twitter.com/e6XHi1JouG